US4058597A - Aluminium salts of betaine chloride and compositions containing the same - Google Patents

Aluminium salts of betaine chloride and compositions containing the same Download PDF

Info

Publication number
US4058597A
US4058597A US05/665,242 US66524276A US4058597A US 4058597 A US4058597 A US 4058597A US 66524276 A US66524276 A US 66524276A US 4058597 A US4058597 A US 4058597A
Authority
US
United States
Prior art keywords
aluminium salt
aluminium
integer
compositions
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/665,242
Inventor
Andre Henri Passedouet
Robert Pipon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Industries SA
Original Assignee
Rhone Poulenc Industries SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Industries SA filed Critical Rhone Poulenc Industries SA
Application granted granted Critical
Publication of US4058597A publication Critical patent/US4058597A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/06—Aluminium compounds
    • C07F5/069—Aluminium compounds without C-aluminium linkages

Definitions

  • This invention relates to new aluminium salts useful as pharmaceuticals and in cosmetology, to a process for their preparation and compositions containing them.
  • the preferred aluminium salt is that of formula I wherein a is 2, b is 5 and c is 13.
  • the aluminium salts of general formula I are prepared by the process which comprises reacting an aluminium alkoxide with betaine chloride in aqueous solution, the aluminium alkoxide being used in an amount corresponding to the proportion of aluminium in the desired product of general formula I.
  • the aluminium alkoxide used is one obtained from an aliphatic alcohol containing 1 to 3 carbon atoms, such as aluminium methoxide, ethoxide or isopropoxide.
  • a suspension of aluminium isopropoxide in isopropanol is reacted with an aqueous solution of betaine chloride at a temperture between 50° and 80° C.
  • the preferred molar ratio of aluminum isopropoxide to betaine chloride is 2.5:1.0.
  • aluminium salts of general formula I obtained according to the aforedescribed process can be isolated from the reaction mixture after concentrating the latter the residue obtained with a poor solvent such as acetone or diethyl ether.
  • aluminium salts of general formula I possess useful pharmacological properties coupled with a low toxicity. They are particularly valuable as anti-ulcer agents, as agents which protect the gastro-intestinal mucous membrane, and as agents which protect the liver. They also have a good cicatrizant activity.
  • mice In mice, the 50% lethal dose (LD 50 ) is generally greater than 5 g./kg. animal body weight when administered orally.
  • aluminium salts of the present invention have anti-perspirant and deodorant properties which make them particularly useful in cosmetology.
  • aluminium salt of general formula I wherein a is 2, b is 5 and c is 13 has proved particularly active.
  • Aluminium isopropoxide (205.8 g.; 1.005 mole) suspended in anhydrous isopropanol (300 cc.) is added, over the course of 10 minutes, to betaine chloride (61.8 g.; 0.402 mole) dissolved in distilled water (3,000 cc.) at 60° C. After the end of the addition, the reaction mixture is stirred and heated at 60° C. for 3 hours. The isopropanol is then removed by distillation under reduced pressure. After filtering the reaction mixture to remove insoluble impurities, the filtrate is concentrated to dryness under reduced pressure. The white product obtained is taken up several times in diethyl ether, filtered off and then dried under reduced pressure at 40° C. This gives an aluminium salt of betaine chloride (124.6 g.; 0.188 mole) in the form of a white powder corresponding to the formula: ##STR3##
  • the present invention includes within its scope pharmaceutical compositions comprising, as active ingredient, at least one of the salts of general formula I in association with a pharmaceutical carrier or coating.
  • the invention includes especially such preparations made up for oral, parenteral or rectal administration or topical, especially dermal application, e.g. as ointments.
  • Solid compositions for oral administration include tablets, pills, powders and granules.
  • the active compound is admixed with at least one inert diluent such as sucrose, lactose or starch.
  • the compositions may also comprise, as is normal practice, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate.
  • Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water and liquid paraffin.
  • compositions may also comprise adjuvants, such as wetting, emulsifying and suspending agents, and sweetening, flavouring and aromatizing agents.
  • adjuvants such as wetting, emulsifying and suspending agents, and sweetening, flavouring and aromatizing agents.
  • the compositions according to the invention, for oral administration also include capsules of absorbable material such as gelatin containing the active substance with or without the addition of diluents or excipients.
  • Preparations according to the invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions or emulsions.
  • compositions for rectal administration are suppositories which contain, in addition to the active substance, excipients such as cacao butter or a suitable wax base.
  • the percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained.
  • compositions according to the invention are particularly useful in human therapy in the treatment of gastrites and various gastralgias induced by other medicines, and in the treatment of ulcerous maladies (gastric or duodenal ulcers and peptic ulcers).
  • the dosages depend on the desired effect and on the duration of the treatment; they are generally between 1 and 5 g. per day when administered orally to an adult.
  • the physician will decide the posology considered appropriate, taking into account the age, weight and other factors intrinsic to the patient being treated.
  • magnesium stearate 0.005 g.
  • the present invention is also concerned with anti-perspirant and deodorant cosmetic compositions which comprise at least one of the aluminium salts of general formula I in association with a suitable cosmetic vehicle, and optionally with microbicidal agents.
  • compositions can be in various forms and, more particularly, in the form of lotions, creams, powders, milks or aerosols.
  • the percentage by weight of the salt(s) of general formula I is genrally between 0.01% and 5%.
  • the lotions are either aqueous solutions or aqueous-alcoholic solutions which contain between 0.01% and 1% by weight of salt of general formula I.
  • the creams are emulsions of a mineral, animal or vegetable oil in water which contain between 0.01% and 5% by weight of salt of general formula I.
  • compositions when in the form of powders contain between 0.01% and 5% by weight of salt of general formula I mixed with talc and with one or more anti-agglomerating agents.
  • compositions when in a form suitable for use as an aerosol, comprise an aqueous-alcoholic solution of a salt of general formula I and at least one propellant under pressure.
  • Example illustrates a cosmetic composition according to the invention.
  • a deodorant and anti-perspirant talc having the following composition is prepared.
  • magnesium stearate 5 g.

Abstract

Aluminum salts of the formula: ##STR1## WHEREIN A IS AN INTEGER FROM 1 THROUGH 4, B IS AN INTEGER FROM 1 THROUGH 5 AND C IS AN INTEGER FROM 1 THROUGH 13, THE NUMBERS REPRESENTED BY THE INDICES A, B AND C BEING CONNECTED BY THE RELATIONSHIPS 3B = A + C AND THE RATIO B/A IS EQUAL TO OR GREATER THAN 1 AND LESS THAN OR EQUAL TO 2.5, ARE NEW COMPOUNDS POSSESSING PHARMACOLOGICAL, ANTI-PERSPIRANT AND DEODORANT PROPERTIES.

Description

This invention relates to new aluminium salts useful as pharmaceuticals and in cosmetology, to a process for their preparation and compositions containing them.
The new aluminium salts of this invention are those compounds of the general formula: ##STR2## wherein a represents an integer from 1 to 4 (preferably 1 or 2), b represents an integer from 1 to 5 and c represents an interger from 1 to 13, the numbers represented by the indices a, b and c being connected by the relationships 3b = a + c and the ratio b/a is equal to or greater than 1 and less than or equal to 2.5. The preferred aluminium salt is that of formula I wherein a is 2, b is 5 and c is 13.
According to a feature of the present invention, the aluminium salts of general formula I are prepared by the process which comprises reacting an aluminium alkoxide with betaine chloride in aqueous solution, the aluminium alkoxide being used in an amount corresponding to the proportion of aluminium in the desired product of general formula I.
Preferably, the aluminium alkoxide used is one obtained from an aliphatic alcohol containing 1 to 3 carbon atoms, such as aluminium methoxide, ethoxide or isopropoxide. In its most preferred aspect, a suspension of aluminium isopropoxide in isopropanol is reacted with an aqueous solution of betaine chloride at a temperture between 50° and 80° C. The preferred molar ratio of aluminum isopropoxide to betaine chloride is 2.5:1.0.
The aluminium salts of general formula I obtained according to the aforedescribed process can be isolated from the reaction mixture after concentrating the latter the residue obtained with a poor solvent such as acetone or diethyl ether.
The aluminium salts of general formula I possess useful pharmacological properties coupled with a low toxicity. They are particularly valuable as anti-ulcer agents, as agents which protect the gastro-intestinal mucous membrane, and as agents which protect the liver. They also have a good cicatrizant activity.
In animals the salts of general formula I, used at doses of between 0.25 and 1 g./kg. animal body weight and administered orally, have proved active against gastric ulcers induced experimentally (i) in rats in accordance with the technique of H. Shay et al. Gastroenterology, 5, 43 (1945), or (ii) in guinea-pigs by the administration of histamine in accordance with the technique of W. Anderson and J. Watt, J. Physiol. (London), 147, 52 P (1959).
In mice, the 50% lethal dose (LD50) is generally greater than 5 g./kg. animal body weight when administered orally.
Furthermore, the aluminium salts of the present invention have anti-perspirant and deodorant properties which make them particularly useful in cosmetology.
The aluminium salt of general formula I wherein a is 2, b is 5 and c is 13 has proved particularly active.
The following Examples illustrate the preparation of the new aluminium salts of the present invention.
EXAMPLE 1
Aluminium isopropoxide (205.8 g.; 1.005 mole) suspended in anhydrous isopropanol (300 cc.) is added, over the course of 10 minutes, to betaine chloride (61.8 g.; 0.402 mole) dissolved in distilled water (3,000 cc.) at 60° C. After the end of the addition, the reaction mixture is stirred and heated at 60° C. for 3 hours. The isopropanol is then removed by distillation under reduced pressure. After filtering the reaction mixture to remove insoluble impurities, the filtrate is concentrated to dryness under reduced pressure. The white product obtained is taken up several times in diethyl ether, filtered off and then dried under reduced pressure at 40° C. This gives an aluminium salt of betaine chloride (124.6 g.; 0.188 mole) in the form of a white powder corresponding to the formula: ##STR3##
EXAMPLE 2
Following the procedure of Example 1 but starting with betaine chloride (199.5 g.; 1.3 mole) in water (1,300 cc.) and aluminium isopropoxide (266 g.; 1.3 mole) in isopropanol (260 cc.), an aluminium salt of betaine chloride (257 g.) is obtained in the form of a white powder, melting at a temperature above 260° C,. and corresponding to the formula: ##STR4##
The present invention includes within its scope pharmaceutical compositions comprising, as active ingredient, at least one of the salts of general formula I in association with a pharmaceutical carrier or coating. The invention includes especially such preparations made up for oral, parenteral or rectal administration or topical, especially dermal application, e.g. as ointments.
Solid compositions for oral administration include tablets, pills, powders and granules. In such solid compositions the active compound is admixed with at least one inert diluent such as sucrose, lactose or starch. The compositions may also comprise, as is normal practice, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate. Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water and liquid paraffin. Besides inert diluents such compositions may also comprise adjuvants, such as wetting, emulsifying and suspending agents, and sweetening, flavouring and aromatizing agents. The compositions according to the invention, for oral administration, also include capsules of absorbable material such as gelatin containing the active substance with or without the addition of diluents or excipients.
Preparations according to the invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions or emulsions.
Compositions for rectal administration are suppositories which contain, in addition to the active substance, excipients such as cacao butter or a suitable wax base.
The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained.
The compositions according to the invention are particularly useful in human therapy in the treatment of gastrites and various gastralgias induced by other medicines, and in the treatment of ulcerous maladies (gastric or duodenal ulcers and peptic ulcers).
In human therapy, the dosages depend on the desired effect and on the duration of the treatment; they are generally between 1 and 5 g. per day when administered orally to an adult.
In general, the physician will decide the posology considered appropriate, taking into account the age, weight and other factors intrinsic to the patient being treated.
The following Example illustrates pharmaceutical compositions according to the invention.
EXAMPLE 3
Tablets having the following composition are prepared in accordance with the usual technique:
aluminium salt of betaine chloride of formula II depicted hereinbefore: 0.500 g.
starch: 0.150 g.
precipitated silica: 0.095 g.
magnesium stearate: 0.005 g.
The present invention is also concerned with anti-perspirant and deodorant cosmetic compositions which comprise at least one of the aluminium salts of general formula I in association with a suitable cosmetic vehicle, and optionally with microbicidal agents.
The compositions can be in various forms and, more particularly, in the form of lotions, creams, powders, milks or aerosols.
In these cosmetic compositions the percentage by weight of the salt(s) of general formula I is genrally between 0.01% and 5%.
The lotions are either aqueous solutions or aqueous-alcoholic solutions which contain between 0.01% and 1% by weight of salt of general formula I.
The creams are emulsions of a mineral, animal or vegetable oil in water which contain between 0.01% and 5% by weight of salt of general formula I.
The compositions when in the form of powders contain between 0.01% and 5% by weight of salt of general formula I mixed with talc and with one or more anti-agglomerating agents.
The compositions, when in a form suitable for use as an aerosol, comprise an aqueous-alcoholic solution of a salt of general formula I and at least one propellant under pressure.
The following Example illustrates a cosmetic composition according to the invention.
EXAMPLE 4
A deodorant and anti-perspirant talc having the following composition is prepared.
aluminium salt of betaine chloride of formula II depicted hereinbefore: 5 g.
magnesium stearate: 5 g.
titanium oxide: 5 g.
salicylic acid; 2 g.
talc: q.s.p. 100 g. We claim:

Claims (6)

1. An aluminium salt of the formula: ##STR5## wherein a is an integer from 1 through 4, b is an integer from 1 through 5 and c is an integer from 1 through 13, the numbers represented by the indices a, b and c being connected by the relationships 3b = a + c and the ratio b/a is equal to or greater than 1 and less than or equal to 2.5.
2. An aluminium salt according to claim 1 wherein a is 1 or 2.
3. An aluminium salt according to claim 1 wherein a is 2, b is 5 and c is 13.
4. An aluminium salt according to claim 1 wherein a is 1, b is 1 and c is 2.
5. Pharmaceutical composition useful as an anti-ulcer agent which comprises, as active ingredient, an effective amount of an aluminium salt of the formula depicted in claim 1, wherein a, b and c are as defined in claim 1, in a pharmaceutical carrier.
6. Anti-perspirant or deodorant cosmetic composition which comprises an aluminium salt of the formula depicted in claim 1, wherein a, b and c are as defined in claim 1, in a cosmetic vehicle selected from the group consisting of lotion, cream, powder, milk and aerosol, the composition containing from 0.01% to 5% by weight of said aluminium salt.
US05/665,242 1975-03-11 1976-03-09 Aluminium salts of betaine chloride and compositions containing the same Expired - Lifetime US4058597A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR75.07555 1975-03-11
FR7507555A FR2303536A1 (en) 1975-03-11 1975-03-11 NEW ALUMINUM SALTS, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM

Publications (1)

Publication Number Publication Date
US4058597A true US4058597A (en) 1977-11-15

Family

ID=9152403

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/665,242 Expired - Lifetime US4058597A (en) 1975-03-11 1976-03-09 Aluminium salts of betaine chloride and compositions containing the same

Country Status (11)

Country Link
US (1) US4058597A (en)
JP (1) JPS51113829A (en)
BE (1) BE839402A (en)
CH (1) CH594604A5 (en)
DE (1) DE2610225A1 (en)
DK (1) DK102276A (en)
ES (1) ES445961A1 (en)
FR (1) FR2303536A1 (en)
GB (1) GB1479132A (en)
LU (1) LU74518A1 (en)
NL (1) NL7602210A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009887A (en) * 1985-10-31 1991-04-23 Aikoh Co., Ltd. Deodorant composition in the form of a gel
WO2004089325A1 (en) * 2003-04-04 2004-10-21 Colgate-Palmolive Company Glycine-free antiperspirant salts with betaine for enhanced cosmetic products
US20040241122A1 (en) * 2003-05-30 2004-12-02 Christine Popoff High efficacy gel with low glycol content
WO2005025523A2 (en) * 2003-09-08 2005-03-24 Colgate-Palmolive Company Antiperspirant clear gel with low glycol content
US20050158261A1 (en) * 2002-12-09 2005-07-21 Xiaozhong Tang High efficacy, low irritation aluminum salts and related products
US20070110687A1 (en) * 2005-11-16 2007-05-17 Jairajh Mattai Antiperspirant Compositions
US7704531B2 (en) 2005-02-18 2010-04-27 Colgate-Palmolive Company Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141154T1 (en) * 1990-06-05 1996-08-15 Cultor Oy METHOD FOR REDUCING THE IRRITATIVE PROPERTIES OF COSMETIC COMPOSITIONS
DE19855934A1 (en) * 1998-12-04 2000-06-08 Beiersdorf Ag Use of betaines as antiperspirants
US20040198998A1 (en) * 2003-04-04 2004-10-07 Marian Holerca Glycine-free antiperspirant salts with betaine for enhanced cosmetic products
US7105691B2 (en) 2003-06-26 2006-09-12 Colgate-Palmolive Company Aluminum / zirconium / glycine antiperspirant actives stabilized with Betaine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2508787A (en) * 1948-07-08 1950-05-23 Chattanooga Medicine Co Dichloro aluminum aminoacetate hydrate deodorant composition
US2641604A (en) * 1949-05-28 1953-06-09 Chattanooga Medicine Co Aluminum salts of dibasic amino acids
US3539605A (en) * 1968-01-30 1970-11-10 Nalco Chemical Co Ion exchange method of preparing quaternary ammonium compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2508787A (en) * 1948-07-08 1950-05-23 Chattanooga Medicine Co Dichloro aluminum aminoacetate hydrate deodorant composition
US2641604A (en) * 1949-05-28 1953-06-09 Chattanooga Medicine Co Aluminum salts of dibasic amino acids
US3539605A (en) * 1968-01-30 1970-11-10 Nalco Chemical Co Ion exchange method of preparing quaternary ammonium compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Brevet Special De Medicament No. 7569M, 1/1970, Serviere, 7 pages. *
Chemical Abstracts, 1972, vol. 77, pp. 269-270. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009887A (en) * 1985-10-31 1991-04-23 Aikoh Co., Ltd. Deodorant composition in the form of a gel
US20050158261A1 (en) * 2002-12-09 2005-07-21 Xiaozhong Tang High efficacy, low irritation aluminum salts and related products
US7311898B2 (en) 2002-12-09 2007-12-25 Colgate-Palmolive Company High efficacy, low irritation aluminum salts and related products
WO2004089325A1 (en) * 2003-04-04 2004-10-21 Colgate-Palmolive Company Glycine-free antiperspirant salts with betaine for enhanced cosmetic products
AU2004228006B2 (en) * 2003-04-04 2009-05-28 Colgate-Palmolive Company Glycine-free antiperspirant salts with betaine for enhanced cosmetic products
US7204976B2 (en) 2003-05-30 2007-04-17 Colgate-Palmolive Company High efficacy gel with low glycol content
US20040241122A1 (en) * 2003-05-30 2004-12-02 Christine Popoff High efficacy gel with low glycol content
WO2005025523A3 (en) * 2003-09-08 2005-06-09 Colgate Palmolive Co Antiperspirant clear gel with low glycol content
US20070196308A1 (en) * 2003-09-08 2007-08-23 Christine Popoff Antiperspirant clear gel with low glycol content
WO2005025523A2 (en) * 2003-09-08 2005-03-24 Colgate-Palmolive Company Antiperspirant clear gel with low glycol content
AU2004272034B2 (en) * 2003-09-08 2009-11-05 Colgate-Palmolive Company Antiperspirant clear gel with low glycol content
US7704531B2 (en) 2005-02-18 2010-04-27 Colgate-Palmolive Company Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine
US20070110687A1 (en) * 2005-11-16 2007-05-17 Jairajh Mattai Antiperspirant Compositions
US20110014144A1 (en) * 2005-11-16 2011-01-20 Colgate-Palmolive Company Antiperspirant compositions

Also Published As

Publication number Publication date
DE2610225A1 (en) 1976-09-23
DK102276A (en) 1976-09-12
ES445961A1 (en) 1977-08-16
CH594604A5 (en) 1978-01-13
JPS51113829A (en) 1976-10-07
NL7602210A (en) 1976-09-14
FR2303536A1 (en) 1976-10-08
FR2303536B1 (en) 1978-08-04
GB1479132A (en) 1977-07-06
BE839402A (en) 1976-09-10
LU74518A1 (en) 1977-01-11

Similar Documents

Publication Publication Date Title
US4057636A (en) Antihypertensive pyridylguanidine compounds
US4058597A (en) Aluminium salts of betaine chloride and compositions containing the same
US3950418A (en) Vitamin A acid amides
IL29569A (en) 1,4-dihydropyridine derivatives and their production
US5190947A (en) Codeine salt of a substituted carboxylic acid, its use and pharmaceutical compositions thereof
EP0218027B1 (en) Novel guanidinomethylbenzoic acid derivatives
DK149025B (en) ANALOGY PROCEDURE FOR PREPARING WATER SOLUBLE SALTS OF N- (2-PYRIDYL) -2-METHYL-4-HYDROXY-2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE-1,1-DIOXIDE
IL30782A (en) Amino guanidines
EP0219961B1 (en) Irreversible dopamine-b-hydroxylase inhibitors
EP0028483A1 (en) 1,2,4-Triazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
CA1075702A (en) Process for the preparation of substituted guanidine compounds
US4013699A (en) Aluminium and/or magnesium salts of amino-acids
EP0250264A1 (en) Irreversible dopamine-Beta-hydroxylase inhibitors
JPS6072843A (en) Novel derivatives of 4-phenyl-4-oxo-2-butenoic acid, manufacture, use as drug and composition
EP0009608B1 (en) N-phenethylacetamide compounds, processes for their preparation and therapeutic compositions containing them
US4285935A (en) Dehydropeptide compounds, their production and their medical use
CA1181402A (en) Substituted 2-amino-3,4-dihydropyridine derivatives, their production and their medicinal use
US4994484A (en) 1-(3-(2-hydroxy-3-alkylaminopropoxy)-2-thienyl)-3-phenyl-1-propanones and process for the preparation of the same
US4198431A (en) Alkyl N-(3-trifluoromethylphenyl)-anthranilate
JPS60158150A (en) 1,4-naphthoquinone derivatives
HU193385B (en) Process for production of derivatives of diamine and medical preparatives consisting of such substances
EP0037710B1 (en) Thiazole derivatives
US4171360A (en) Phosphinegold (I) salts having antiarthritic activity
US4246278A (en) Medicaments having an antiphlogistic action
GB2211187A (en) Tromethamine salt of 1-methyl-¼-oxo-alpha-(phenylcarbamoyl)-2-pyrrolepropio- nitrile